Key Takeaways TEM stock surged 82.4% in a year, sharply outperforming its industry peers and the broader market. TEM's Genomics sales more than doubled as testing volumes rose 33% and Ambry integration lifted efficiency. Data & Services revenues grew 26.1%, Paige boosted AI scale, and TEM posted positive adjusted EBITDA. Tempus AI (TEM) has shown impressive momentum in the past 12 months, with its shares rising 82.4%. This has significantly outperformed the industry, which grew 2.6%, as well as the S&P 500 ...

Core Insights - Tempus AI, Inc. is advancing the adoption of AI in precision medicine, particularly in gastrointestinal cancers [1] Group 1: Company Developments - Eight abstracts from Tempus have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium [1] - The symposium is scheduled to take place from January 8 to 10 in San Francisco, California [1] Group 2: Research Commitment - The research presented by Tempus at the ASCO GI symposium reflects the company's commitment to advancing progress in gastrointestinal cancers [1] - The presentations demonstrate the effectiveness of utilizing AI in cancer research [1]

SAN FRANCISCO--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for neurology, today announced Amy Gordon Franzen as its new Chief Executive Officer. Amy will lead the company's next stage of growth, leveraging its success in Parkinson's Disease, where it has established StrivePD as the industry's preeminent AI platform and patient app. The company is actively expanding this platform to address additional neurological conditions, including Alzheimer's disease and other forms of dementia. Co- fou ...

Key Takeaways TEM ended Q3 2025 with $760M cash, no current debt, and manageable leverage backing a stable balance sheet. TEM reached a positive adjusted EBITDA of $1.5M, marking an inflection point as revenues scale. TEM carries $1.25B in long-term debt, while its cash strength supports AI investment and data expansion. At the end of the third quarter of 2025, Tempus AI (TEM) reported a stable and well-capitalized balance sheet, reflecting prudent financial management and a strengthening operating profile. ...

Group 1: Ark Invest's Strategic Trades - Ark Invest made significant trades focusing on Tempus AI Inc. and Kodiak AI Inc., indicating a strategic interest in the AI sector [1] - The firm also executed notable transactions involving Roku Inc. and Shopify Inc. [1] Group 2: Tempus AI Trade - Ark Invest purchased 32,627 shares of Tempus AI through the ARK Genomic Revolution ETF and 195,999 shares via the ARK Innovation ETF, totaling approximately $14.8 million at a closing price of $64.70 [2] - There is a surge in interest in Tempus AI, reflecting bullish sentiment in the market [3] Group 3: Kodiak AI Trade - Ark Invest added 53,302 shares of Kodiak AI to its ARK Autonomous Technology & Robotics ETF, valued at approximately $554,340 with a closing price of $10.40 [4] - Kodiak AI is a key player in the driverless truck industry, aligning with Ark's focus on innovative technologies [4] Group 4: Roku Trade - Ark Invest sold 109,254 shares of Roku from ARKK, valued at approximately $12.5 million with a closing price of $114.68 [5] - Roku's third-quarter earnings report showed net revenue of $1.211 billion, up 14% year over year, exceeding the Street consensus estimate [5] Group 5: Shopify Trade - Ark Invest reduced its stake in Shopify by selling 24,447 shares from ARKK, valued at approximately $4.06 million with a closing price of $166.21 [6] - Recent updates from Shopify, including the Winter 2026 Edition, have reinforced confidence in its long-term growth [7] Group 6: Other Key Trades - Ark Invest sold 3,558 shares of Natera Inc. and 7,228 shares of Guardant Health Inc. from ARKG, while buying 47,587 shares of Personalis Inc. for ARKG [9]

Core Insights - Investors are showing a bullish stance on Tempus AI (NASDAQ:TEM), with significant options trading activity indicating potential upcoming developments [1][2] - The overall sentiment among large investors is split evenly between bullish and bearish positions, with a notable preference for call options [2] - Analysts have set an average target price of $80.0 for Tempus AI, reflecting positive market expectations [9][10] Options Trading Activity - A total of 13 uncommon options trades were identified for Tempus AI, with 11 call options amounting to $963,056 and 2 put options totaling $85,500 [1][2] - The projected price window for Tempus AI based on recent options activity is between $50.0 and $70.0 [3] - Detailed analysis of volume and open interest indicates strong investor interest in options with strike prices from $50.0 to $70.0 over the past 30 days [4][5] Company Overview - Tempus AI Inc is a technology company focused on healthcare data, utilizing AI to enhance the accuracy and personalization of laboratory tests [8] - The company is currently trading at $64.45, reflecting a 3.35% increase, with a trading volume of 3,670,308 [11]

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best AI stocks to buy according to analysts. On December 8, TD Cowen reaffirmed its Hold rating on Tempus AI, Inc. (NASDAQ:TEM), with an $88 price target. According to TD Cowen, analyst Dan Brennan will be joined by a co-analyst in covering the healthcare AI company. The added coverage will focus on leveraging TD Cowen’s artificial intelligence abilities to examine Tempus AI’s database and commercial applications. Citing the company’s vast data assets as a com ...

Tempus AI, Inc. (NASDAQ:TEM) is among the 12 Best Genomics Stocks to Invest In. Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM) TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95. The shares were still rated as a buy by analyst Kyle Mikson. As noted by Canaccord, the sector momentum that started in the latter half of 2025 can continue into 2026, based on a preview of its coverage of life science instruments and diagn ...

Core Insights - Investor confidence in Tempus AI (TEM) is currently affected by near-term factors, despite the company's strong long-term strategic positioning [2] - The company's Data and Services segment shows growth through multi-quarter bookings, with significant additions in the third quarter and large contract wins [2] - Uncertainty regarding the timing of revenue conversion from these bookings is impacting market sentiment [2][3] Company Performance - Management indicates that bookings convert into revenues over multi-year periods, which does not lead to immediate top-line growth [3] - Data revenues are typically recognized in the second half of the year due to customer budgeting cycles, resulting in potential quarterly revenue variability [3] - Backlog growth enhances long-term visibility, but may lead to continued revenue and margin variability in the near term [3] Competitive Landscape - Tempus plans a gradual increase in MRD as reimbursement dynamics improve, but faces intense competition from high-sensitivity assays expected to enter the market [4] - The Paige acquisition is anticipated to increase losses by a mid-single-digit million amount per quarter, alongside ongoing investments in AI compute infrastructure [4] Peer Analysis - GE HealthCare's radiopharmaceuticals business presents strong growth potential but carries substantial execution risks, particularly with the integration of Nihon Medi-Physics [5] - Exact Sciences' financial results are highly dependent on the performance of its Cologuard test, with significant revenue generation reliant on the success of its Screening and Precision Oncology tests [6] Stock Performance - Over the past year, Tempus' shares have increased by 81.4%, significantly outperforming the industry growth of 1.3% and the S&P 500's 19.5% increase [7] Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 7.02X, compared to the industry average of 5.77X, indicating an expensive valuation [9] Earnings Estimates - In the past 30 days, the loss per share estimate for Tempus AI for 2025 has narrowed by 1 cent to 64 cents [10]

Industry Overview - The global healthcare information systems market was valued at $519.23 billion in 2024 and is projected to reach approximately $1,773.33 billion by 2034, with a CAGR of 13.07% from 2025 to 2034 [1] - Rising government spending on healthcare infrastructure and digital transformation is a key driver of market expansion [2] Technology Adoption - There is an increasing emphasis on patient satisfaction, data security, and administrative cost efficiency, leading to the adoption of technologies such as big data, 3D printing, blockchain, and artificial intelligence [2] Company Analysis: Tempus AI - Tempus has seen its shares surge by 85.1% over the past year, indicating strong market performance [6] - The company focuses on advancing precision medicine through AI, with a robust growth in diagnostics and a strong cash position of $764.3 million [7] - Tempus has entered multi-year strategic collaborations with AstraZeneca and Pathos, gaining access to over 300 petabytes of multimodal data, enhancing its competitive position [8] - The demand for digital healthcare and medical information systems is expected to benefit Tempus significantly [9] Company Analysis: Hims & Hers Health - Hims & Hers has experienced a 36.3% increase in shares over the past year, reflecting solid growth [6] - The company has reached 2.5 million subscribers, driven by demand for weight-loss offerings and mental health services [11] - Hims & Hers is expanding its offerings with new specialties in women's and men's health, enhancing its market presence [12][13] - The company is in a transition phase regarding profitability, with investments aimed at long-term growth despite current margin pressures [14] Valuation and Price Targets - Tempus and Hims & Hers are trading at forward 12-month price-to-sales (P/S) ratios of 7.16 and 2.83, respectively, with Hims & Hers trading at a discount to Tempus [15] - The average price target for Tempus is $88.92, suggesting a 38.4% upside, while Hims & Hers has an average price target of $45.92, indicating a 32.5% upside [16][19] Conclusion - Tempus is well-positioned to capitalize on the growing adoption of AI-driven precision medicine due to its expanding diagnostics franchise and strategic partnerships [21] - Hims & Hers demonstrates strong potential for sustained top-line growth through rapid subscriber growth and expanding specialty offerings [21] - Based on current performance and analyst price targets, Hims & Hers may be a stronger investment option compared to Tempus [22]